Preclinical research highlights a novel glycan-targeting approach for gastric cancer
NEW TAIPEI CITY, Taiwan, Oct. 20, 2025 -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that an abstract describing preclinical research on its first-in-class antibody-drug conjugate (ADC), GNX1021, has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26, 2025, in Boston, Massachusetts.
The abstract, titled "Targeting branched Lewis B/Y glycans with GNX1021: A novel ADC approach for HER2-low gastric cancer," describes preclinical work characterizing GNX1021's novel glycan-targeting mechanism. GNX1021 is engineered to recognize branched Lewis B/Y, a tumor-associated glycan highly expressed in gastric and other epithelial tumors but with limited expression in healthy tissue, potentially enabling a new level of tumor selectivity.
GlycoNex anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026 for a first-in-human clinical trial of GNX1021. The program builds on GlycoNex's proprietary GlycoSH antibody bank and extensive expertise in glycan-directed antibody and ADC development.
Presentation Details:
|
Event: |
American Association for Cancer Research (AACR) NCI-EORTC |
|
Session: |
Poster Session B |
|
Abstract Title: |
Targeting branched Lewis B/Y glycans with GNX1021: A novel ADC |
|
Date and Time: |
Friday, October 24, 12:30-4:00 pm |
|
Location: |
Hynes Convention Center, Boston; Level 2, Exhibit Hall D |
About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.
Contact s for GlycoNex, Inc.
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
dirish@tiberend.com
Media Relations
Eric Reiss
ereiss@tiberend.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
